Author Archive: Jim Greenwood

Jim Greenwood

Jim joined BIO as President & CEO in 2005 after representing the eighth district of Pennsylvania in the U.S. House of Representatives for six terms.  He had worked with BIO while in Congress on stem cell research and other health issues, and has since learned so much about the many applications of the science in food and agriculture and in industrial and environmental biotechnology.

Due to its revolutionary research and development in issues ranging from feeding the world by increasing crop yields to healing the world with new medicines to providing cleaner sources of energy, Jim is a passionate champion for biotechnology. When visiting member companies, he is inspired by executives and scientists who are united in their mission to help patients, farmers and other consumers lead a better life.

Prior to Congress, Jim served in the Pennsylvania House of Representatives and Pennsylvania Senate for six years each.  He and his wife Tina live in historic Washington Crossing, Pennsylvania (where he has participated in the re-enactment of George Washington crossing the Delaware River on Christmas Day in 1776). He enjoys fishing, birding and scuba diving.

You can find him on Facebook at

Latest Posts

Wall Street Journal: Patients Deserve Better


In case you missed it, The Wall Street Journal published my Letter to the Editor this morning.  I make the point that the problem isn’t innovative new treatments from America’s biopharma industry but rather the complex web of health-insurance schemes patients must navigate to access needed medicines. Here is the text of the letter: “Innovative treatments and cures have radically transformed how we treat disease—saving and improving lives and providing tremendous benefits to patients and Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

WSJ Article Cherry Picks Cost, Ignores Value of Medicines

Jim Greenwood

Today’s Wall Street Journal story, “Price Increases Drive Drug Firms’ Revenue” reaffirms that old chestnut, “…a little information is a dangerous thing…”  When speaking to the complexities of the costs and benefits of America’s healthcare system, a publication like the Wall Street Journal should not cherry pick one aspect of that system to cover while ignoring the rest. Unfortunately and uncharacteristically, in this case, the paper focused on particular costs while ignoring value. In fact, Read More >

Health  |  1 Comment  |  Email This Post
Tags: ,

Dr. Scott Gottlieb: A Clintonian Misdirection on Drug Prices

Hillary Clinton

Today’s Wall Street Journal contains an excellent op-ed by Dr. Scott Gottlieb, a physician and resident fellow at the American Enterprise Institute. Dr. Gottlieb takes aim at the recent proposal offered by the campaign of Secretary Hillary Clinton to aggressively regulate the price of innovative prescription medicines. BIO shared many of those concerns in our statement and a related blog post. Dr. Gottlieb notes, “It’s important to distinguish between new medicines that are priced at Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Ezekiel Emanuel’s Flawed Solution

Jim Greenwood

In a New York Times op-ed today, Dr. Ezekiel Emanuel proposes “The Solution to Drug Prices.” The piece is problematic in many respects, but we agree with one of his primary contentions: in discussions about drug prices, value is the real issue. This point was nicely made in a recent Times piece, where it quoted Crystal Bedford, whose five year old daughter, Marley, suffers from a rare genetic disease, Rhizomelic Chondrodysplasia Punctata (RCPD). A treatment Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Send us Your BIO 2016 Session and Speaker Ideas

BIO International Convention

Even though BIO 2015 in Philadelphia was just two months ago, we already are hard at work getting ready for 2016 and the BIO International Convention in San Francisco (June 6-9, 2016). Our team at BIO is always imagining new ways to improve your experience, to make the most of your time and your meetings and to ensure that you are hearing directly from the key science, policy and investment leaders that allow you to Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: ,